… metabolism between leukemia stem cells and malignant stem cells from solid tumors. …
malignant stem cells from solid tumors. Because metabolic properties are highly specific to the cell …

… Cancer stem cells (CSCs) are highly tumorigenic cell types that reside within specific
areas of tumor microenvironment (TME), and are endowed with self-renewal and resistance …

… Solid tumors are generally treated with surgery or medical approaches [1,2]. Treatment
approaches include immunotherapies, chemotherapies, and radiotherapies [3,4,5,6]. One of the …

… The world of small molecules in solid tumors as cancer stem cells (CSCs), circulating tumor
cells (CTCs) and cancer-associated fibroblasts (CAFs) continues to be under-debated, but …

… [ 62-67 ] Al–Hajj et al. isolated tumorigenic and nontumorigenic subsets of cancer cells
from breast tumor biopsies as the first evidence of CSCs in solid tumors. They have serially …

… Cytotoxic therapies are currently used for the treatment of solid tumors and hematological
malignancies in the absence of other first-line, effective and less toxic treatments. Beside the …

… However, in solid tumors biopsies or resection samples, CSC biomarkers can be
measured using immunohistochemistry or reverse transcription polymerase chain reaction (PCR), …

… tumor microenvironment (TME), highlighting the potential use of cancer stem cells in tumor
… Solid tumors are the most common forms of cancer, and they account for high levels of …

… Resistance to chemotherapy and radiotherapy consistently observed in both solid tumors
and leukemia CSCs [76]. For example, in acute myeloid leukemia, hematopoietic …

… T cell therapy for solid tumor This section discusses the fundamental challenges of CAR T
cell therapy in solid tumors … hand, targeting cancer stem cells that are closely related to tumor …